4:13 PM
 | 
Apr 18, 2017
 |  BC Extra  |  Company News

Novartis, Allergan planning NASH combo trial

Novartis AG (NYSE:NVS; SIX:NOVN) and Allergan plc (NYSE:AGN) said they will test a combination including a farnesoid X receptor (FXR; NR1H4) agonist from Novartis and cenicriviroc (formerly TBR-652) from Allergan in a Phase IIb trial to treat...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >